Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NOTEWORTHY A deficiency of the pulmonary vasodilative vasoactive intestinal peptide (VIP) has been suggested to be involved in the pathophysiology of pulmonary hypertension (PH). Supplementation of VIP as an aerosol is hampered by the fact that it is rapidly inactivated by neutral endopeptidases (NEP) located on the lung surface. Coapplication of thiorphan, an NEP 24.11 inhibitor, could augment the biological effects of inhaled VIP alone. A stable pulmonary vasoconstriction with a threefold increase of pulmonary artery pressure was established by application the thromboxane mimetic U46619 in the isolated rabbit lung model. VIP and thiorphan were either applied intravascularly or as an aerosol. VIP caused a significant pulmonary vasodilation either during intravascular application or inhalation. These effects were of short duration. Thiorphan application had no effects on pulmonary vasoconstriction per se but significantly augmented the effects of VIP aerosol. Thiorphan, not only augmented the maximum hemodynamic effects of VIP aerosol, but also led to a significant prolongation of these effects. VIP causes pulmonary vasodilation in a model of acute experimental PH. The hemodynamic effects of VIP aerosol can be significantly augmented via coapplication of an NEP inhibitor.
https://journals.physiology.org/doi/full/10.1152/ajplung.00317.2014
Pulmonary Arterial Hypertension Market Size Worth $9.8 Billion By 2027. The global pulmonary arterial hypertension market size is expected to reach USD 9.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 5.6% over the forecast period.
https://www.grandviewresearch.com/press-release/global-pulmonary-arterial-hypertension-pah-market-size-report
NEW & NOTEWORTHY These studies for the first time present comprehensive data on the relative characterization of vasoactive intestinal peptide (VIP) receptors in the intestinal mucosa. Vasoactive intestinal peptide receptor 1 (VPAC1) was identified as the predominant receptor with higher levels in the colon compared with the small intestine and was mainly localized to the apical membrane. In addition, the findings in the human tissues were consistent with VPAC1 expression in the mouse intestine and open possibilities to target colonic tissues with VIP for treating diseases such as inflammatory bowel disease.
https://journals.physiology.org/doi/full/10.1152/ajpgi.00081.2017
The global inflammatory bowel disease treatment market size was valued at USD 15.9 billion in 2018 and is expected to register a CAGR of 4.4% from 2018 to 2026. Presence of strong pipeline products for the treatment of inflammatory bowel disease (IBD) is anticipated to drive the market over the forecast period.
https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market
Dr. McCoy, may I have VIP treatment? —-
What’s the matter with you?
Kidney dialysis. Dialysis??? God, what is this, the Dark Ages?...Beam me up Scotty!!!
It is important to bear in mind that RA is a dynamic disease in its development, so a complete understanding of how RA develops over time is important to set up therapies that prevent disease progression rather than treating its symptoms [35]. The importance of the neuroimmune network in joint homeostasis has been shown. Indeed, several neuropeptides identified in joint tissues, including vasoactive intestinal peptide (VIP), have been suggested to have a role as neuroosteological regulators in bone metabolism. VIP is a homeostatic and immunoregulatory peptide involved in the control of both innate and adaptive immune response. It has only one chain of 28 amino acids, with some residues crucial to its functions, which sequence is highly conserved during evolution. It belongs to the secretin/glucagon family of peptides which share an a-helix structure [36]. This neuropeptide can act locally or systematically as it is produced by sympathetic nerve endings, lymphocytes, or even FLS in the joint [37, 38]. VIP is involved in a broad range of functions through its binding to its specific G-protein-coupled receptors, VPAC1 and VPAC2 [39]. Healing effects of exogenous administration of VIP in animal models of inflammatory/autoimmune diseases have been described; specifically, VIP prevents arthritis in a CIA model through its anti-inflammatory and immunomodulatory actions [40, 41]. In humans, “ex vivo” effects of VIP have been demonstrated in lymphocytes, macrophages, and FLS [21, 38, 42]. In summary, VIP is a microenvironment mediator capable of modulating all the stages mentioned above in RA from the arrival of pathogens to the differentiation of Th cells. It exerts a direct antimicrobial activity against a variety of pathogens [43, 44] and modulates TLR expression in several cells, even in FLS from RA patients [45–47]. In addition, VIP decreases proinflammatory mediators in lymphocytes and FLS from RA patients [21, 38, 48–50] and modulates the differentiation of several Th cells from RA patients, including a decrease in the pathogenic profile and plasticity of some of them [21, 50, 51]. In addition to the role of VIP in “ex vivo” samples from RA patients, endogenous VIP also plays a major role in patients with RA, allowing to stratify patients with early RA for therapeutic decision making in the “window of opportunity” [52]. VIP gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis [43, 53]. Indeed, lower levels of its receptor, VPAC1, in PBMCs are associated with more severe inflammation and higher disease activity in RA patients [54].
Taking all this into consideration, this review provides a deep description of the role of this anti-inflammatory mediator, VIP, in the differentiation and function of Th subsets in rheumatoid arthritis, capable to modulate all the stages between the arrival of pathogens and the differentiation of Th cells in RA.
https://www.hindawi.com/journals/jir/2018/6043710/
The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period.
https://www.grandviewresearch.com/press-release/global-rheumatoid-arthritis-therapeutics-market
Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for bronchodilatory, immunomodulatory and mucus secretion modulating effects by interacting with the VIP receptors VPAC1 and VPAC2, it is discussed to be a promising target for pharmaceutical intervention in common diseases such as COPD and bronchial asthma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852716/
The chronic obstructive pulmonary disease (COPD) space across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and Australia, is set to rise from $9.9 billion in 2015 to around $14.1 billion by 2025, representing a compound annual growth rate of 3.7%, according to research and consulting ...
https://drug-dev.com/copd-market-set-to-hit-14-1-billion-by-2025/
The US treatment market for asthma will rise in value from $11.7 billion in 2013 to an estimated $14 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 2.6%, says business intelligence provider GBI Research.
https://drug-dev.com/us-asthma-treatment-market-value-to-hit-14-billion/
May the FORCE be with you!! >>>>
If we look at the coronavirus map, we can see that strains G and GR are the most frequent across Europe and Italy. According to the available data, GH strain seems close to non-existence in Italy, while it occurs more frequently in France and Germany. This seems to confirm the effectiveness of last months' containment methods.>>>>>>>>>>>>>>>>>>>>>>
In North America, the most widespread strain is GH, while in South America we find the GR strain more frequently. In Asia, where the Wuhan L strain initially appeared, the spread of strains G, GH and GR is increasing. These strains landed in Asia only at the beginning of March, more than a month after their spread in Europe. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Globally, strains G, GH and GR are constantly increasing. Strain S can be found in some restricted areas in the US and Spain. The L and V strains are gradually disappearing.
https://www.sciencedaily.com/releases/2020/08/200803105246.htm
POTUS Trump risk factors...
Now is right!! It is too late for yesterday!! >>>>>>>>>>>>>>>>>>>>
Quote: We can only hope the exposure the President brings lights a fire under the FDA's a$$. I believe I'm only 1 of millions of Americans that want these drugs available. If they are safe and show efficacy make them available to us now!
There are two known receptors for the vasoactive intestinal peptide (VIP) termed VPAC1 and VPAC2. These receptors bind both VIP and pituitary adenylate cyclase-activating polypeptide (PACAP) to some degree. Both receptors are members of the 7 transmembrane G protein-coupled receptor family. https://en.wikipedia.org/wiki/Vasoactive_intestinal_peptide_receptor
Then... “Summary:
RLF-100 blocks the COVID-19 Virus, prevents a cytokine storm, heals the lungs and improves blood oxygenation with a mortality reduction of oyver 90% in the most severe cases.”
https://www.reddit.com/r/investing/comments/ihjz24/rlftf_the_most_promising_covid19_stock_drug/
Two thumbs up for the article!! The more we know...!!
Hm, do people start feeling better in minutes??? How it works is still a mystery...
iSquash, the MeadowFox claimed “protects ACE2 receptor” but according to NeuroRX’s RLF-100 pre-print read/page 3, VIP binds to other receptors hence protecting the pulmonary Alveolar Type II cell
https://www.neurorxpharma.com/our-services/rlf-100/
Pulmonary hypertension (PH) leads to an increased right ventricular workload, cardiac failure and death. In idiopathic pulmonary arterial hypertension (PAH) the vasodilating vasoactive intestinal peptide (aviptadil) is deficient. The aim of the present study was to test the acute effects on haemodynamics and blood gases, and the safety, of a single dose of inhaled aviptadil in chronic PH. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>
A total of 20 patients with PH (PAH in nine, PH in lung disease in eight and chronic thromboembolic PH in three) inhaled a single 100-µg dose of aviptadil during right-heart catheterisation. Haemodynamics and blood gases were measured. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Aviptadil aerosol caused a small and temporary but significant selective pulmonary vasodilation, an improved stroke volume and mixed venous oxygen saturation. Overall, six patients experienced a pulmonary vascular resistance reduction of >20%. In patients with significant lung disease, aviptadil tended to improve oxygenation. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>
The pulmonary vasodilating effect of aviptadil aerosol was modest and short-lived, did not cause any side-effects and led to a reduced workload of the right ventricle without affecting systemic blood pressure. Aviptadil inhalation tended to improve oxygenation in patients with significant lung disease. Further studies are needed to evaluate the full therapeutic potential of aviptadil aerosol, including higher doses and chronic treatment.
https://erj.ersjournals.com/content/32/5/1289
Who wants to be friends with SamiAIR???
My understanding is that “viruses infect cells via receptor-mediated fusion, entering the host cell by binding to receptors on its surface.”In the COVID-19 case the key receptor is ACE2. There may be mutations but ACE2 remains the target of COVID-19.
RLF-100 shields the ACE2 receptors and protects host cell from injury.
COVID-19 cases on the rise in Europe but, not in Sweden! Good for them!
How much the upcoming season will tax a health care system that has been stretched is unknown. However, a new report in JAMA Network Open offers a look at the similarities and differences between COVID-19 and seasonal influenza.1 >>>>>>>>>>>>>>>>>>>>>>>>>>>>>
The investigators ran a retrospective cohort study of children at the Children’s National Hospital in the District of Columbia. The children with influenza were diagnosed between October 1, 2019, and June 6, 2020. Children with laboratory-diagnosed COVID-19 were diagnosed between March 25, 2020, and May 15, 2020. The researchers looked at the rates of hospitalization, mechanical ventilator use, association between underlying medical conditions, and admission to the intensive care unit.
https://www.drugtopics.com/view/study-compares-clinical-features-of-covid-19-and-seasonal-influenza
estimated that the annual burden of influenza included 31.4 million outpatient visits, 334,185 hospitalizations, and direct medical costs of $10.4 billion.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612050/
Can a biosimilar be approved for an indication that is approved for the reference product even if the biosimilar is not directly studied in that indication? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Yes, a biosimilar product may be approved for an indication without direct studies of the biosimilar in that indication. If the total evidence in the biosimilar application supports a demonstration of biosimilarity for at least one of the reference product’s indications, then it is possible for the biosimilar manufacturer to use data and information to scientifically justify approval for other indications that were not directly studied by the biosimilar manufacturer. This concept is called “extrapolation” and is critical to the goals of an abbreviated pathway—improving access and options at a potentially lower cost.
https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval
Biosimilars raise complex questions for patients, doctors and regulators. Unlike generics, which are exact copies of the chemical medicines they are modeled after, biosimilars retain slight differences from the original biologic medicines.1 These differences exist because biologics and biosimilars are made with distinct strains of living cells resulting in medicines that can’t be identically copied.1 >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
There are specific considerations involved in the approval process for biosimilars. The U.S. Food and Drug Administration (FDA) requires the maker of a biosimilar to show that its medicine, when compared to the original biologic, functions the same and is made up of similar components. More specifically, biosimilars must react the same way in the body — a concept known as pharmacokinetics and pharmacodynamics (PK/PD) — and have equivalent effectiveness and safety as the original biologic.2 >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
One specific consideration relevant to the FDA and important for doctors and patients to understand is extrapolation. This concept allows the maker of a biosimilar to perform clinical trials in one appropriate disease and then potentially use the data to support the approvals for all of the original medicine’s approved indications. For example, the immunosuppressant medicine infliximab has been studied in and received approval to treat six conditions, including rheumatoid arthritis, Crohn’s disease and plaque psoriasis. The FDA has approved two biosimilar versions of infliximab for all six, even though they only underwent testing for a few of those...
https://www.gene.com/stories/extrapolation-explained
the latter has a “history of taking already known molecules and moving them very quickly through the FDA”
https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/
This time of year is called “flu season.” In the United States, flu viruses are most common during the fall and winter months. Flu activity often begins to increase in October and November. Most of the time flu activity peaks between December and February, and it can last as late as May.
https://www.cdc.gov/flu/season/faq-flu-season-2019-2020.htm
The global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022, increasing at a compound annual growth rate (CAGR) of 3.0% from 2017 through 2022.
https://www.bccresearch.com/market-research/pharmaceuticals/the-global-influenza-market.html
Per virtual attendee:
*US patent 8178489B2 - May be useful in future applications.
*Cooperative agreement with NIH (NIAD) to test VIP not only against COVID, but also against influenza and other pulmonic viruses.
*BARDA is evaluating for National Stockpile.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158457496
To your point —- In 2019, the global Steroid-Corticosteroids market size was USD 4368.5 million and it is expected to reach USD 5965.4 million by the end of 2026, with a CAGR of 4.5% during 2021-2026.
https://www.marketwatch.com/press-release/steroid-corticosteroids-market-size-2020-data-is-available-for-global-separately-with-impact-of-domestic-and-global-market-top-players-share-future-challenges-revenue-industry-growth-and-top-players-analysis-to-2026-2020-08-27
Did you announce an “All Aboard” the $RLFTF train??
I do recall that sad case because of the similarities/symptoms COVID-19 has with Ebola virus. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
“... binds to uninfected dendritic cells (DCs) and macrophages, in a process dependent on the glycosylation pattern of shed GP and on cellular Toll-like receptor 4 (TLR4). The binding of shed GP resulted in the activation of DCs and macrophages, and induced the release of cytokines, which were sufficient to increase the permeability of endothelial barriers. These data suggest that the release of shed GP from infected cells leads to the dysregulation of the host immune response and the modulation of remote target cells, such as endothelial cells, resulting in increased inflammation and vascular permeability, which are two characteristics of fatal EBOV infection. https://www.nature.com/articles/nrmicro3412
Is RLF-100 the drug to cover all bases (ace2)? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> “Since identifying the possible route of infection has major implications for understanding the pathogenesis and future treatment strategies for SARS, the present study investigated the localization of ACE2 protein in various human organs (oral and nasal mucosa, nasopharynx, lung, stomach, small intestine, colon, skin, lymph nodes, thymus, bone marrow, spleen, liver, kidney, and brain). The most remarkable finding was the surface expression of ACE2 protein on lung alveolar epithelial cells and enterocytes of the small intestine. Furthermore, ACE2 was present in arterial and venous endothelial cells and arterial smooth muscle cells in all organs studied. In conclusion, ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS-CoV. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167720/
We’ll soon find out but not soon enough for the 28 y/o doctor.
Have you ever seen that? What? A colt stand up that fast!!
Our CEO Dr. Jonathan Javitt spoke with @RfwrightLSL about how we turned a 10-year-old drug into a promising drug in development for the treatment of critical #COVID19 in just 10 weeks.
— NRx Pharmaceuticals (@NRxPharma) September 18, 2020
Watch now on Life Science Leader: https://t.co/GZNOgAUpDT#RLF100 #aviptadil pic.twitter.com/Xiggte17xU
Adult patients with prolonged duration of ECMO constitute the major risk population. Ventilator-associated pneumonia and bloodstream infections form the main sources of sepsis in these patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223121/
Proding the FDA for approval???
FDA Approval: FDA is required to review and approve the request for EUA.
https://www.astho.org/Programs/Preparedness/Public-Health-Emergency-Law/Emergency-Use-Authorization-Toolkit/Comparing-Emergency-Use-Authorization-to-Investigational-New-Drug---Investigational-Device-Exemption-Protocols-Fact-Sheet/
RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol
https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html
More importantly, type 2 cells manufacture surfactant that coats the lung and is essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.~CISION, PRnewswire
Respiratory diseases are leading causes of death and disability in the world. About 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf
Besides the disease burden, COPD is also associated with substantial economic costs. In the European Union, the total direct costs for COPD are estimated to be about 3% (€38.6 billion) of the total health care budget
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1179-7
Cigarette smoke is an important risk factor for COPD and it is known to adversely affect surfactant. In a series of 20 smoker, non-asthmatic COPD patients compared with 5 nonsmoker healthy controls we found a marked decrease (about 6-7 times) of total phospholipids in bronchoalveolar lavage fluids.
https://www.karger.com/Article/PDF/196100
Think that RLF-100 will help alleviate this condition?
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.
Section 564 of the FD&C Act was amended by the Project Bioshield Act of 2004 and was further amended by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), the 21st Century Cures Act of 2016, and Public Law 115-92 of 2017.
Please note: a determination under section 319 of the Public Health Service Act that a public health emergency exists, such as the one issued on January 31, 2020, does not enable FDA to issue EUAs. A separate determination and declaration are needed under section 564 of the Federal Food, Drug and Cosmetic Act to enable FDA to issue EUAs, provided other statutory criteria are met. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
Quote:
Relief continues to run on the thinnest of infrastructure, outsourcing key functions, with no apparent signs of internal ramp-up efforts, internal talent acquisition, etc.
I don't think they can run so thin with what is shaping up to be a worldwide covid solution. And... they don't seem to be in "holy crap we need to get some people on board fast" mode.~Uncle Gee Gee Relief Therapeutics Holding AG (RLFTF)>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
It is quite common for boutique pharma companies, biotech firms, and university labs to license their intellectual property (a new compound) to large pharmaceutical companies. In such cases, the big pharma companies finance and manage the R&D process and, if successful, market the drugs. In exchange for use of their intellectual property, the outlicensing organizations receive licensing contracts that promise some combination of fixed payments, event-specific milestone payments, and revenue- or profit-based royalties. https://doi.org/10.1111/jacf.12252
Why not acquire?? How much, 50bn?? Does $4 B of company valuation translates to $50/s??>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Quote: Valuation is impossible atm but if I'd guess how much the company was sold for, my "guess" would be 100B+ easy... Its just that though, a guess....
Effective treatment for a global pandemic afflicting millions and disrupting world economies, what is that worth? Oh you say it might help with other respiratory afflictions too, stack that valuation on top of the pandemic treatment value as if even it matters. Until I have some sound rational idea(Not for the foreseeable future), I'm not moving anything. 0.2% Minority Owner, see you at the annual shareholders meeting! ~J-Belford, post 9/18/20
Trying to post a “thumbs up” in agreement with what you said but instead I got two question marks.
U+1F44D
Quote: Check out the tweet in the last 24 hours from Rep. Andy Harris, MD of Maryland, who is one of three people on the DMC reviewing RLF-100, and who has direct links to the White House. Regarding Operation Warp Speed, he said, "...this ultimate public private partnership has our nation on the cusp of a medical miracle, and once approved, millions of doses will be available immediately."~The Whale>>>>>>>>
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Data monitoring committees act best in an advisory capacity, making recommendations to the group responsible for running the trial, possibly with recourse to an arbiter if this group disagrees with its recommendations. Deciding that a trial should be stopped early is never easy because of the range of issues and responsibilities that must be taken into consideration. Good research governance means that the organisers of trials need to give serious and early consideration to arrangements for monitoring accumulating data particularly the constitution, roles, responsibilities, and procedures of data monitoring committees.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516093/
True???
Of the 100 best selling drugs, nearly 80 percent have extended their patents at least once, and 50 percent have extended their patents multiple times to block generic competition and maintain their stranglehold on critical medications.>>>>>>>>>>>>>>>>>>>
In fact, a recent series of studies conducted by Initiative for Medicines, Access, and Knowledge (I-MAK) found that of the top 12 grossing drugs in America, over 125 patent applications were filed and 71 were granted per drug. These patent applications attempted to block generic competition from entering the market by an average of 38 years, nearly double 20-year protection normally intended under U.S. patent laws. https://www.csrxp.org/the-truth-about-big-pharmas-patent-abuse/
Platform deals for preclinical or discovery-stage assets were also in evidence. Gilead’s buy-in to Galapagos' R&D engine is the biggest example, but its deals with Nurix and Goldfinch were also focused on tapping into their discovery expertise to yield multiple candidates, in protein degradation and kidney disease, respectively.
https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2019
It is quite common for boutique pharma companies, biotech firms, and university labs to license their intellectual property (a new compound) to large pharmaceutical companies. In such cases, the big pharma companies finance and manage the R&D process and, if successful, market the drugs. In exchange for use of their intellectual property, the outlicensing organizations receive licensing contracts that promise some combination of fixed payments, event-specific milestone payments, and revenue- or profit-based royalties.>>>>>>>>>>>>>>>>>>>>>>
The authors show how to estimate the expected present value of the future cash flows promised by such licensing deals. The complicating factor in such valuations is that the licensing contracts are essentially derivative contracts written on drugs in development, which as the authors showed in a paper published in this journal a year ago, are themselves compound options on marketed drugs. The authors use the valuation example from the earlier paper, along with a proposed licensing deal, and walk the reader through the process of valuing the licensing deal's cash flows.
https://doi.org/10.1111/jacf.12252
With the announcement of a mega-merger in January—Bristol-Myers Squibb (BMS)’s $74 billion acquisition of Celgene—2019 was set early on to be a big year for dealmaking. Licensing deals were also plentiful, with the top 10 licensing deals in 9 months of 2019 having a total disclosed deal value of $34 billion, an increase of 10% from the $31 billion in the corresponding period in 2018. In this feature, we highlight some of the major mergers and acquisitions (M&As) and licensing deals in 2019, with the help of data and analysis from Clarivate Analytics...
https://www.nature.com/articles/d43747-020-00828-4
Biopharma deals of 2019
From trial site news... Have you tried to contact this doctor at Houston Methodist in the Medical Center ?
Houston Methodist Hospital
Contact: Jihad Georges Youssef, MD 713-441-3948 jgyoussef@houstonmethodist.org
Principal Investigator: Jihad Georges Youssef, MD
Goog trial news Aviptadil...look in comments
So, it is ok to ask for billions$$$ when we talk about a “maybe” vaccine, is that it?
https://www.washingtonpost.com/health/2020/09/16/vaccine-distribution-roadmap/
Does Aviptadil have a problem with safety??? Do vaccines have a problem with safety and/or efficacy?
“The findings already are being challenged by some because they conflict with those of another report almost a year ago that raised serious questions about the drug's safety and efficacy. That report claimed the harms are understated and called government stockpiles of the antivirals a waste of money. Critics are latching on to the involvement of drugmaker Roche in the new study as evidence its findings are questionable even though authors say Roche had no active role in the new report. >>>>>>>>>>>>>>>>>>>>>>>>>>>>
“That's the conclusion I would have expected from a Roche-sponsored reanalysis,” said Dr. Peter Doshi, assistant professor of pharmaceutical health services research at the University of Maryland. Doshi was part of a team to review a Cochrane study published last year in The BMJ, which questioned government stockpiling of antiviral flu medications.”
https://www.modernhealthcare.com/article/20150129/NEWS/301299956/tamiflu-controversy-reignited-by-new-study
Dr. Harris is one among several analyzing the data. Is he capable? Is he publicly asking for billions$$$?
https://thehill.com/homenews/house/517001-congressman-who-denounced-mask-wearing-overseeing-the-trial-of-a-drug-to-treat
Harris defended his membership in a statement obtained by The Hill, saying, "I have a Master of Health Science degree from the Hopkins school of public health, which involves training in biostatistics (that's a matter of public record, which you probably already knew)."
"I have been an investigator on numerous [National Institutes of Health] NIH grants and published numerous papers that involved complex statistical analysis, and have been involved in clinical research studies as a principal investigator," he added. ~The Hill
I am thinking manufacturers of inhalers in the USA...??? How many are out there ??? Sorry getting ready to take family to doctor’s appointment. Have a great day everyone!
Also, if the U.S. government can ramp up production of ventilators in the private sectors of the economy, can it ramp up production of RFL-100 with inhaler manufacturers, in the millions? Perhaps we may see that happen.